Selected article for: "clinical study and initial treatment"

Title: 2017 ACVIM Forum Research Abstract Program
  • Document date: 2017_6_15
  • ID: ri2w5iby_712
    Snippet: Our results suggest that, following cessation of immunosuppressive doses of cyclosporine, T-cell expression of IL-2 and IFN-c will begin to return to pre-treatment values within the initial 24 hours. In some dogs, IL-2 and IFN-c expression return to pretreatment values within 3 days of stopping cyclosporine, but other dogs may require an additional recovery day. Interestingly, upon recovery, both IL-2 and IFN-c expression exceed pre-treatment val.....
    Document: Our results suggest that, following cessation of immunosuppressive doses of cyclosporine, T-cell expression of IL-2 and IFN-c will begin to return to pre-treatment values within the initial 24 hours. In some dogs, IL-2 and IFN-c expression return to pretreatment values within 3 days of stopping cyclosporine, but other dogs may require an additional recovery day. Interestingly, upon recovery, both IL-2 and IFN-c expression exceed pre-treatment values, suggesting a potential rebound effect following the cessation of cyclosporine therapy. Additional studies are required to determine the timing of post-cyclosporine recovery of T-cell function in dogs with naturally occurring immune-mediated disorders. The hemostatic efficacy and safety of Yunnan baiyao (YB) has been demonstrated across multiple species. Despite the widespread anecdotal use of YB in veterinary medicine for dogs with bleeding tendencies, few studies have evaluated its efficacy in dogs. The primary objective of this study was to evaluate the effect of YB on clinical hemorrhage following nasal biopsy in dogs as measured by blood loss and time to stop bleeding. A secondary objective was to evaluate the effect of YB on measures of coagulation including buccal mucosal bleeding time (BMBT) and thromboelastography (TEG).

    Search related documents:
    Co phrase search for related documents
    • additional study and clinical hemorrhage: 1
    • bleeding time and blood loss: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • bleeding time and BMBT buccal mucosal bleeding time: 1
    • bleeding time and buccal mucosal: 1, 2
    • bleeding time and buccal mucosal bleeding time: 1, 2
    • blood loss and clinical hemorrhage: 1
    • BMBT buccal mucosal bleeding time and buccal mucosal: 1
    • BMBT buccal mucosal bleeding time and buccal mucosal bleeding time: 1